Free Trial
NASDAQ:IMVT

Immunovant Q4 2025 Earnings Report

Immunovant logo
$15.71 -0.37 (-2.30%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$15.55 -0.16 (-1.02%)
As of 08/1/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.72
Beat/Miss
Beat by +$0.08
One Year Ago EPS
-$0.52

Immunovant Revenue Results

Actual Revenue
$0.16 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunovant Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 29, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Immunovant's Q1 2026 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Immunovant Earnings Headlines

UBS Group Increases Immunovant (NASDAQ:IMVT) Price Target to $18.00
Immunovant Appoints Eric Venker as New CEO
I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.
See More Immunovant Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email.

About Immunovant

Immunovant (NASDAQ:IMVT), a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

View Immunovant Profile

More Earnings Resources from MarketBeat